Jan 29th 2013 - Edison Investment Research today published a report on Innate Pharma entitled "Kir Royale". In summary, the report says:
Innate’s partner Bristol Myers Squibb has started two large Phase I studies with the anti-KIR antibody IPH2102 given in combination with Yervoy (ipilimumab) and separately with the high-profile anti-PD-1 antibody nivolumab in solid tumours, marking a significant expansion of the programme. Innate has also started a Phase II trial of IPH2102 in AML, following promising Phase I data. A single-agent Phase IIa trial of IPH2101 in MM has rendered disappointing data, but interim results from a Phase I trial in combination with lenalidomide were more encouraging.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »